Chloramphenicol: what we have learned in the last decade

Area of Science:

• Pharmacology
• Infectious Diseases
• Microbiology

Background:

• Chloramphenicol exhibits unique properties, being bacteriostatic but bactericidal against key pathogens like *Haemophilus influenzae*, *Streptococcus pneumoniae*, and *Neisseria meningitidis*.
• Its clinical efficacy against meningeal pathogens is well-documented, making it a crucial option for specific severe infections.

Purpose of the Study:

• To review the comparable pharmacokinetics and efficacy of oral and intravenous chloramphenicol.
• To highlight the spectrum of serious infections treatable with chloramphenicol.
• To discuss the toxicity profile and strategies for its mitigation.

Main Methods:

• Review of existing literature on chloramphenicol's properties, efficacy, and safety.
• Analysis of clinical data regarding its use in pediatric infections, typhoid fever, anaerobic infections, meningitis, brain abscesses, and rickettsial infections.
• Evaluation of toxicity data, including aplastic anemia and gray syndrome, and methods for minimizing these risks.

Main Results:

• Oral and intravenous chloramphenicol show comparable kinetics and efficacy.
• The antibiotic is effective against a range of serious infections, particularly those caused by *Haemophilus influenzae*, *Streptococcus pneumoniae*, and *Neisseria meningitidis*.
• Toxicity, including rare aplastic anemia and gray syndrome, can be minimized through recommended dosing and therapeutic drug monitoring.

Conclusions:

• Chloramphenicol remains an important inpatient antibiotic for life-threatening infections.
• Despite potential toxicities, judicious use and monitoring ensure its continued therapeutic value.
• Increased use in recent years has not led to significant increases in resistance or toxicity reports.